Moreover, in vivo experiments were performed to validate the therapeutic efficacy of FHD on NS, and the potential mechanism (PI3K-Akt pathway) and hub targets [prostaglandin-endoperoxide synthase 2 (PTGS2), mitogen-activated protein kinase 1 (MAPK1), and interleukin 6 (IL-6)] were uncovered. The gene discussed is IL6; the disease is hypoalphalipoproteinemia, primary, 1.